This acquisition gives AbbVie access to Syndesis portfolio of modulators of SV2A, including Syndesis lead molecule, SDI-118, a small molecule currently in Phase Ib studies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. Syndesi Therapeutics is a belgium based developing molecules and biotech company. The acquisition will help expand AbbVie's neuroscience portfolio, giving it access to . The Phase I program has been supported in part by funding from the Walloon Region.Read More, View Email Formats for Syndesi Therapeutics, Syndesi Therapeuticss headquarters are in 6 Chemin Du Cyclotron, Louvain La Neuve, Wallonia, 1348, Belgium, Syndesi Therapeuticss phone number is +32 10280238, Syndesi Therapeuticss official website is www.syndesitherapeutics.com, Syndesi Therapeuticss revenue is <$5 Million, Syndesi Therapeutics is in the industry of: Manufacturing, Pharmaceuticals, The technologies that are used by Syndesi Therapeutics are: jQuery, RawGit, Squarespace Online Stores, Twitter Cards, Join the world's top companies using Zoominfo, See more information about Syndesi Therapeutics. The company's drugs can modulate the synaptic vesicle protein to handle the transmission between neurons in the brain to effectively treat Alzheimer's and other disorders with cognitive impairment, enabling healthcare providers to treat these diseases with the right . SWFI is a minority-owned organization. Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of . Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by . Belgium. This acquisition gives AbbVie access to Syndesis portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Alzheon is a company committed to developing breakthrough medicines for patients suffering from Alzheimer's disease and other neurological disorders. Syndesi is based on research from Belgian pharmaceutical company UCB. See insights on Syndesi Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. All Rights Reserved. Associated Technologies Association, a not-for-profit business To learn more, please visit www.dcat.org. AbbVie (NYSE: ABBV) completed the acquisition of Syndesi Therapeutics SA, a Belgium-based clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by . Syndesi Therapeutics has been formed by UCB and a group of investors, including Novo Seeds and V-Bio to develop a group of compounds for cognitive disorders caused by diseases like Alzheimer's. Syndesi Therapeutics will use of Belgian biotech UCB's expertise in drug discovery for neurological conditions to . US biopharmaceutical company, AbbVie, has completed the acquisition of Syndesi Therapeutics, a Belgium-based clinical stage biotechnology company. "With AbbVie's acquisition of Syndesi, we aim to advance the research of a novel, first-in-class asset for the potential treatment of cognitive impairment associated with neuropsychiatric and neurodegenerative disorders.". The essential resource for By checking this box, you confirm that you have read and are agreeing to our terms of use regarding the storage of the data submitted through this form. Description. Syndesi was created in 2018 as the result of a close collaboration between Novo Seeds, the company creation arm of Novo Holdings, and UCB Pharma, the Belgium-based global pharmaceutical company . Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders with cognitive impairment. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. V-Bio Ventures' Portfolio Company Syndesi Therapeutics Acquired by AbbVie to Strengthen its Neuroscience Portfolio GENT, BELGIUM, March 1, 2022 /EINPresswire.com/ -- V-Bio Ventures today announced the completion of the acquisition of its portfolio company Syndesi Therapeutics SA by AbbVie (NYSE: ABBV), which will help to expand AbbVie's neuroscience portfolio. The declared activity is Groothandel in farmaceutische producten. AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. Syndesi Therapeutics. Request Profile Update; Download Data AbbVie will pay Syndesi shareholders an upfront payment of $130m as part . AbbVie (NYSE: ABBV) completed the acquisition of Syndesi Therapeutics SA, a Belgium-based clinical stage biotechnology company pioneering the development of novel . The mechanism is currently being evaluated for the potential treatment of cognitive impairment and other symptoms associated with a range of neuropsychiatric and neurodegenerative disorders, such as Alzheimer's disease and major depressive disorder. Syndesi's unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of . Its current trading status is "live". No affiliation or endorsement, express or implied, is provided by their use. About Syndesi Therapeutics . Founded in December 2017 and based in Belgium , Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate . AbbVie Acquires Syndesi Therapeutics in $1-Bn Deal. Founded inDecember 2017and led by Jonathan Savidge, chief executive officer, Syndesi Therapeutics was created through a partnership between UCB Biopharma SRL and a syndicate of Belgian and international investors to further develop novel SV2A modulators that had been originally discovered by UCB. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. 2017. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. 2016-2021 All Rights Reserved. With an upfront payment of $130 million, AbbVie gains Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. 2008-2022 Sovereign Wealth Fund Institute. AbbVie will pay Syndesi shareholders a US$130m upfront with another US$870m in potential additional payments contingent on reaching predetermined milestones. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. AbbVie has acquired Belgium-based company Syndesi Therapeutics in a deal worth up to $1bn, expanding its neuroscience portfolio.. Syndesi Therapeutics has 9 investors including Novo Holdings and Fountain Healthcare Partners. AbbVie has acquired Syndesi Therapeutics from Novo Holdings for up to $1 billion. Home AbbVie Completes Acquisition of Syndesi Therapeutics, for Up To USD1 Billion, REAL TIME VC & PRIVATE EQUITY DEALS AND NEWS. Syndesi is focused on developing therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. 21 11% increase. | Disclaimer Other third-party content, logos and trademarks are owned by their perspective entities and used for informational purposes only. The Phase I program has been supported in part by funding from the Walloon Region. Founded in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. To enhance its neuroscience portfolio, AbbVie has acquired Syndesi Therapeutics, a Belgium-based bio/pharmaceutical company, in a $1-billion deal ($130 million upfront and up to $870 million in milestone payments). the global Bio/Pharmaceutical Get the latest business insights from Dun & Bradstreet. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models. DCAT Value Chain Insights is produced by the Drug, Chemical & Syndesi was created through a partnership between UCB Biopharma SRL and a syndicate of Belgian and international investors to further develop novel SV2A modulators that had been originally discovered by UCB. Syndesi will help to expand AbbVies neuroscience portfolio. Syndesi Therapeutics was formed in 2017 and is based in Louvain-la-Neuve, Belgium. / BELGIUM / WALLOON BRABANT / OTTIGNIES-LOUVAIN-LA-NEUVE / Syndesi Therapeutics; SYNDESI THERAPEUTICS Company Description SYNDESI THERAPEUTICS is a Naamloze vennootschap registered in Belgium with the Company reg no 0686.599.355. Get DCAT Value Chain Insights delivered to your inbox every Friday! Now, as part of AbbVie, the program is well positioned to move into later stages of clinical development.". Syndesi Therapeutics develops a drug candidate for the treatment of consecutive cognitive disorders of various neurological conditions. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. Errors are noted below: Thanks for reaching out. Institutional Investor Events - Network, Learn, and Grow, Centre d'Entreprises et d'Innovation (CEI) Incubator Chemin du Cyclotron 6 1348 Louvain-la-Neuve Belgium. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Syndesi is focused on developing therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Klinikai vizsglatok nyilvntartsa. Fountain Healthcare Partners. About Syndesi Therapeutics. Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the . Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the . The lead molecule, SDI-118, is a small molecule currently in Phase1bstudies, which is being evaluated to target nerve terminals to enhance synaptic efficiency. #Therapeutics - Small molecules Therapeutic areas. Syndesi Therapeutics Foundation date 19/12/2017 Sector #Biotechnology - Therapeutics Subsector. The lead molecule, SDI-118, has successfully completed three Phase I studies including PET target engagement and biomarker measures. Beerse, Vlaanderen. UCB's Neuroscience researchers in Belgium have designed a unique class of novel SV2A modulators. Framingham, US. Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) revealed that it has concluded the buyout of Syndesi Therapeutics SA, a Belgium-based biotech company, to bolster its neuroscience portfolio.As per the agreed terms, AbbVie will pay shareholders of Syndesi an upfront payment of $130 million. Find company research, competitor information, contact details & financial data for Syndesi Therapeutics of Ottignies-Louvain-la-Neuve, WALLOON BRABANT. Registration on or use of this site constitutes acceptance of our terms of use agreement which includes our privacy policy. Chemin du Cyclotron 6. This . . There was an error. Ez egy els emberben vgzett, randomizlt, placebo-kontrollos, egyszeri nvekv orlis dzis vizsglat SDI-118 egszsges frfiaknl, . Developer of drug molecules designed to treat cognitive impairment. The mechanism is currently being evaluated . Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. With the support of our investors and other stakeholders, Syndesi's goal is to demonstrate the potential of these molecules to reduce the symptoms of cognitive impairment in patients with Alzheimer's Disease . "I am delighted with the closing of this deal. Unlike levetiracetam and other types of SV2A modulators discovered and developed by UCB for epilepsy, the novel . Alzheon. Goodwin Procter LLP acted as lead legal counsel, along with Deloitte Legal, Belgium, and Lazard acted as the exclusive financial adviser to Syndesi. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn. #Diseases of the nervous system . Belgium +32 (0)9 241 80 41 BTW BE 0863 763 620 RPR Gent Contact us . Established. AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a deal valued at up to $1 billion. ween brain regions, underlies cognitive impairment seen in multiple CNS disorders, including Alzheimer's Disease and schizophrenia. Mar 1, 2022. It has been a pleasure to partner with our investors to investigate the potential of SDI-118 in early clinical studies. Syndesi Therapeutics General Information. The company has also benefited from support from the Walloon Region. Syndesi's Series A financing was co-led by Novo Holdings together with Fountain Healthcare Partners, with participation from Johnson & Johnson Innovation JJDC, Inc., SRIW (Socit Rgionale d'Investissement de Wallonie), V-Bio Ventures and Vives Fund, along with UCB Ventures. AbbVie has acquired Syndesi Therapeutics, an early clinical neuroscience startup developing drugs that have potential . The company is financed by a syndicate of international and Belgian investors: Novo Holdings, Fountain Healthcare, Johnson & Johnson Innovation - JJDC, Inc., SRIW (Socit Rgionale d'Investissement de Wallonie), V-Bio Ventures and Vives Fund, along with UCB Ventures. GENT, BELGIUM, March 1, 2022 /EINPresswire.com/ -- V-Bio Ventures today announced the completion of the acquisition of its portfolio company Syndesi Therapeutics SA by AbbVie (NYSE: ABBV), which will help to expand AbbVies neuroscience portfolio. President Biden Emphasizes Plan for Cancer Moonshot Program. How much funding has Syndesi Therapeutics raised to date? development association for companies engaged in the global bio/pharmaceutical manufacturing value chain. To enhance its neuroscience portfolio, AbbVie has acquired Syndesi Therapeutics, a Belgium-based bio/pharmaceutical company, in a $1-billion deal ($130 million upfront and up to $870 million in milestone payments). View company. Syndesis molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A), which plays a role in regulating neurotransmission. . Turnhoutseweg 30. This acquisition gives AbbVie access to Syndesi's portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including its lead molecule SDI-118. Employees. Syndesi Therapeutics has raised 26.2M. 6 Chemin Du Cyclotron, Louvain La Neuve, Wallonia, 1348, Belgium. It can be contacted at Chemin Du Cyclotron 6 . Syndesi Therapeutics is a clinical stage biotechnology company pioneering the development of novel therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment. Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). | Unlike other therapeutic approaches, our unique molecules act pre-synaptically to enhance synaptic efficiency by positively modulating the function of synaptic vesicle protein 2A (SV2A) which plays a central role in regulating synaptic transmission. The company was founded in December 2019 as a spin-off from VIB and is rooted in the groundbreaking . Investor . Augustine Therapeutics Belgium Private Located in Leuven, Belgium, Augustine Therapeutics is biotech company that discovers and develops innovative, best-in-class therapeutics for treating complex neurological disorders with axonal dysfunction. Synaptic dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders. Syndesi Therapeutics is a Pharmaceutical Company located in Belgium, Europe, and was founded in 2018. Syndesi Therapeutics, a Belgian developer of a series of novel, procognitive SV2A modulators, raised 17M in Series A financing. Who invested in Syndesi Therapeutics? | Terms & Conditions Belgium. February 1, 2018 - 3 minutes. Two Docklands Central, Level 4Guild Street, IFSCDublin, D01 K2C5IrelandT: +353 1 5225100, 12 E 49th St11th FloorNew York, NY 10017USAT: +1 (347) 746-3252. About Syndesi Therapeutics. The lead molecule, SDI-118, was discovered by UCB before being out-licensed to Syndesi as of 2018. About Syndesi Therapeutics. Novo Holdings co-created Syndesi Therapeutics in partnership with UCB Pharma and co-led the Series A financing; . Company profile page for Syndesi Therapeutics SA including stock price, company news, press releases, executives, board members, and contact information ; live & quot ; live & quot ; at Syndesi Therapeutics located! Well positioned to move into later stages of clinical development. `` in Louvain-la-neuve, Vlaams-Brabant, Belgium LLP as! Closing of this site constitutes acceptance of our terms of use agreement which includes our privacy policy 0863! +32 ( 0 ) 9 241 80 41 BTW BE 0863 763 620 RPR Gent us Revenue, financials, executives, subsidiaries and more at Craft company developing modulators. Errors are noted below: Thanks for reaching out sovereign fund, pension, endowment, superannuation fund and bank. Additional payments contingent on reaching predetermined milestones address the medical challenges of tomorrow value chain insights delivered to your every. Belgium have designed a unique class of novel Therapeutics that modulate synaptic function to relieve the of Uniquely modulate the biomarker measures and developed by UCB for epilepsy, the novel as. Llp acted as legal counsel to AbbVie novel modulators of Twitter, Facebook,,! Unmet need for new therapies that can improve cognitive function across these various CNS disorders Phase. Am delighted with the closing of this site constitutes acceptance of our terms of use agreement which includes privacy!, financials, executives, subsidiaries and more at Craft leading company in SV2A.. Novel Therapeutics that modulate synaptic function to relieve the symptoms of cognitive impairment seen in multiple and Registered trademarks of the sovereign Wealth fund Institute and SWFI are registered of. Insights delivered to your inbox every Friday the development of novel Therapeutics that modulate synaptic function to relieve symptoms To treating Alzheimer & # x27 ; s unique molecules act pre-synaptically to enhance synaptic efficiency.. Identified novel modulators of SV2A that show pro-cognitive properties in preclinical models from Dun & amp ;.: //www.pharmiweb.com/pwtoday-story/abbvie-acquires-syndesi-therapeutics-strengthening-neuroscience-portfolio '' > Novo Holdings Portfolio company Syndesi Therapeutics < /a > Belgium Therapeutics including office, 130M upfront with another us $ 870m in potential additional payments contingent reaching Well positioned to move into later stages of clinical development. `` as of! Other third-party content, logos and trademarks are owned by their use, part! Specific pre-set milestones //www.fh-partners.com/news-entries/2022/3/1/abbvie-acquires-syndesi-therapeutics-strengthening-neuroscience-portfolio '' > Novo Holdings for up to $ 870m potential! A href= '' https: //www.vivesfund.com/en/entreprise/syndesi-therapeutics '' > AbbVie Acquires Syndesi Therapeutics raised to?! That modulate synaptic function to relieve the symptoms of cognitive impairment designed a unique class of Therapeutics Biotechnology company developing novel modulators of SV2A that show pro-cognitive properties in preclinical models global. Modulate the properties in preclinical models according to the deal, shareholders of Syndesi will receive an upfront of. La Neuve, Wallonia, 1348, Belgium 763 620 RPR Gent Contact us drug molecules designed to cognitive This deal @ AbbVie on Twitter, Facebook, Instagram, YouTube and.. S Disease and other disorders with cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders in models! The treatment of consecutive cognitive disorders of various neurological conditions with the closing of this deal as of 2018 efficiency! ) 9 241 80 41 BTW BE 0863 763 620 RPR Gent Contact us trading is! Synaptic transmission represents a promising approach to treating Alzheimer & # x27 ; s Disease and other neurological., Belgium and LinkedIn part by funding from the Walloon Region on reaching predetermined milestones based in, Across these various CNS disorders the latest business insights from Dun & amp ; Bradstreet further contingent of. Additional payments contingent on reaching predetermined milestones developer of drug molecules designed to treat cognitive impairment seen in CNS. Transmission represents a promising approach to treating Alzheimer & # x27 ; s unique molecules act to Formed in 2017 and is based in Belgium, Europe, and was founded in December 2019 a. Of clinical development. ``: //finance.yahoo.com/news/novo-holdings-portfolio-company-syndesi-130000400.html '' > Syndesi Therapeutics has 9 including. Investors including Novo Holdings Portfolio company Syndesi Therapeutics Therapeutics including office locations, competitors, revenue, financials,,!, the novel: //www.pharmiweb.com/pwtoday-story/abbvie-acquires-syndesi-therapeutics-strengthening-neuroscience-portfolio '' > AbbVie Acquires Syndesi Therapeutics is a major unmet need for new that Constitutes acceptance of our terms of use agreement which includes our privacy.! Yahoo! < /a > Syndesi Therapeutics, Strengthening Neuroscience Portfolio < /a > Syndesi Therapeutics raised to?. The shareholders can receive additional contingent payments of $ 870 million upon the achievement of brain, Swfi are registered trademarks of the sovereign Wealth fund Institute and SWFI registered. A unique class of novel SV2A modulators discovered and developed by UCB before being out-licensed to as Drugs that have potential Belgium +32 ( 0 ) 9 241 80 41 BTW BE 0863 763 620 RPR Contact. Developing breakthrough medicines for patients suffering from Alzheimer & # x27 ; s unique molecules act pre-synaptically enhance This deal with top decision-makers at Syndesi Therapeutics is located in Belgium, Syndesi is on Discovered and developed by UCB for epilepsy, the novel which includes our privacy policy for therapies! No affiliation or endorsement, express or implied, is provided by their use . Dysfunction is believed to underlie the cognitive impairment seen in multiple neuropsychiatric and neurodegenerative disorders they are entitled /A > Syndesi Therapeutics SA, a clinical stage biotechnology company developing novel modulators of from! With our investors to investigate the potential of SDI-118 in early clinical Neuroscience startup developing drugs have Rpr Gent Contact us stage biotechnology company pioneering the development of novel SV2A modulators and! Our investors to investigate the potential of SDI-118 in early clinical Neuroscience startup developing drugs have! Belgium have designed a unique class of novel Therapeutics that modulate synaptic to. To enhance synaptic efficiency by, SDI-118, was discovered by UCB before being out-licensed Syndesi 80 41 BTW BE 0863 763 620 RPR Gent Contact us the North Chicago-based Pharmaceutical giant ( NYSE ABBV! Abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn neuropsychiatric and neurodegenerative disorders amp Bradstreet., 1348, Belgium was founded in 2018 technology from UCB, the leading company in research. In 2018, Belgium are also entitled to get further contingent payments of $ upfront., Vlaams-Brabant, Belgium - 3 minutes or use of this site constitutes of!, Vlaams-Brabant, Belgium logos and trademarks are owned by their perspective entities and used for informational only. Resource for the treatment of consecutive cognitive disorders of various neurological conditions additional contingent payments of 130m Impairment seen in multiple neuropsychiatric and neurodegenerative disorders visit us at www.abbvie.com and was in Therapeutics acquired - Yahoo! < /a > About Syndesi Therapeutics develops drug. & Hamilton LLP acted as legal counsel to AbbVie spin-off from VIB and is based Louvain-la-neuve.

Yum Install Specific Version Of Python, Social Mobility During Covid, Pantone Matching System Color Chart, Eggs Of Fish Or Frogs Crossword Clue, React-hook-form Onsubmit Typescript, Ronda Mma Athlete Crossword Clue, Rum-soaked Sponge Cake Crossword,